Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism

MLA

Yvo J.M. op den Kamp, et al. “Effects of SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes on Skeletal Muscle Cellular Metabolism.” Molecular Metabolism, vol. 66, Jan. 2022. EBSCOhost, https://doi.org/10.1016/j.molmet.2022.101620.

APA

Yvo J.M. op den Kamp, Anne Gemmink, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Johanna A. Jorgensen, Gert Schaart, Russell Esterline, Diego A. Pava, Joris Hoeks, Vera B. Schrauwen-Hinderling, Sander Kersten, Bas Havekes, Timothy R. Koves, Deborah M. Muoio, Matthijs K.C. Hesselink, Jan Oscarsson, Esther Phielix, & Patrick Schrauwen. (2022). Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism. Molecular Metabolism, 66. https://doi.org/10.1016/j.molmet.2022.101620

Chicago

Yvo J.M. op den Kamp, Anne Gemmink, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Johanna A. Jorgensen, Gert Schaart, et al. 2022. “Effects of SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes on Skeletal Muscle Cellular Metabolism.” Molecular Metabolism 66 (January). doi:10.1016/j.molmet.2022.101620.